Cefuroxime (2nd Gen) Powder for Suspension

Cefuroxime (2nd Gen) Powder for Suspension

Form: Powder for Suspension

Strength: 125 mg/5 mL, 250 mg/5 mL, 500 mg/5 mL

Reference Brands: Ceftin, Zinacef(US & EU)

Category: Antibiotics

Cefuroxime suspension is approved in the EU and US for treating respiratory, urinary, and skin infections. In the EU, brands like Zinacef are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval relies on extensive clinical data; generic formulations are available. Both regions require detailed dossiers and pharmacovigilance plans for approval and ongoing safety monitoring. Due to its widespread use and safety profile, strict regulations on labeling, dosing, and usage are enforced. For expert assistance with dossier preparation, compliance, and registration, visit PharmaTradz. We support seamless market access ensuring adherence to European and American standards for effective antimicrobial therapy.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Colistin (Polymyxin E) Inhalation Solution (Nebulizer)

Strength: 75 mg/2 mL

Form: Inhalation Solution (Nebulizer)

Reference Brands: Coly-Mycin M(US)

View Details Get Enquiry
Colistin (Polymyxin E)

Strength: 150 mg/5 mL, 300 mg/5 mL, 1.5 million IU/vial

Form: Injectable (IV/IM/SC)

Reference Brands: Coly-Mycin M(US)

View Details Get Enquiry
Fosfomycin Oral Sachets or Powder for Suspension

Strength: 3g in a sachet

Form: Oral Sachets or Powder for Suspension

Reference Brands: Zyflo(US)

View Details Get Enquiry
Fosfomycin IV

Strength: 2 g, 4g per vial

Form: Intravenous (IV)

Reference Brands: Zyflo(US)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.